Analysis Mass Tort

GalaFLEX and Phasix: What Patients Should Know About Mesh Used in Breast Surgery

GalaFLEX and Phasix are two names that come up often in breast mesh lawsuits. Both are made by BD, and both are built from a material called P4HB that the body slowly absorbs. They are cleared by the FDA for soft-tissue repair. But the FDA has said that no surgical mesh is cleared or approved for breast surgery. Many patients do not know which mesh, if any, was used in their own surgery. Here is a plain-English guide.

What these products are

GalaFLEX is a knitted mesh, sometimes called a scaffold. There are several versions, including GalaFLEX, GalaFLEX Lite, GalaFLEX 3D and GalaFLEX 3DR. The original GalaFLEX mesh was cleared by the FDA in May 2014.

Phasix is a family of mesh products used mainly in hernia repair. Versions include Phasix Mesh and Phasix ST Mesh.

What P4HB is

Both product lines are made from poly-4-hydroxybutyrate, or P4HB. It is a material made by bacteria through fermentation. Over time, the body breaks it down and absorbs it. In its FDA clearance summary, Phasix mesh was described as being essentially absorbed within 12 to 18 months.

The idea is that the mesh supports tissue while the body builds new tissue in its place.

How the mesh is used

The FDA says these BD products are cleared for “the repair and reinforcement of soft tissue where weakness exists.” That includes uses like hernia repair.

Some surgeons have also used this kind of mesh in breast procedures. Placed inside the breast, it can act as an “internal bra” to support tissue or an implant. This may happen during:

  • Breast lifts
  • Breast reductions
  • Breast augmentation
  • Breast reconstruction, including after a mastectomy
  • Implant revision

What the FDA has said

On November 9, 2023, the FDA told doctors that BD had updated warnings and precautions on nine GalaFLEX and Phasix products. The FDA said the safety and effectiveness of surgical mesh in breast surgery has not been determined. It added that no surgical mesh products are cleared or approved by the FDA for breast surgery.

The FDA did not recall GalaFLEX or Phasix in that letter. It also said it was not recommending that patients without symptoms have mesh removed.

What lawsuits allege

Women who have sued allege that they were not properly warned about risks when this mesh was used in breast surgery. Reported complications include infection, pain, swelling, seroma, mesh exposure and the need for revision or removal surgery.

BD and the related companies can dispute these claims. No court has found them liable. You can read more about GalaFLEX breast mesh claims and how they are reviewed.

How to find out what mesh you have

You may not know if mesh was used, or which one. These records may help:

  • Your operative report, which describes what the surgeon did
  • Implant or device records, which may list the product name and lot number
  • Stickers or labels from the product packaging, which are sometimes placed in your chart
  • Hospital or surgery center records
  • Records from any later revision or removal surgery

You can ask your surgeon’s office or hospital for copies of your records. You do not need these records before talking to a lawyer about breast mesh complications. No attorney can promise a settlement or outcome, but a review can start with what you know today.

This article is general information about how these cases work. It is not legal advice, it does not create an attorney-client relationship, and no two claims are alike. If something here sounds like your situation, the useful next step is a conversation about the facts.

Sources and citations

Statutes, regulations, agency material and decisions referred to above.

  1. Labeling Updates for BD Mesh Products – Letter to Health Care ProvidersU.S. Food and Drug AdministrationNovember 9, 2023. Source of the product list, the clearance wording, the FDA’s statements on mesh in breast surgery and its recommendation on patients without symptoms.
  2. 510(k) Premarket Notification K140533 — GalaFLEX MeshU.S. Food and Drug AdministrationCited for the May 21, 2014 clearance of the original GalaFLEX mesh, submitted by Tepha, Inc.
  3. 510(k) Premarket Notification K142818 — Phasix MeshU.S. Food and Drug AdministrationMarch 31, 2015. FDA clearance summary for Phasix Mesh, submitted by Davol Inc., a subsidiary of C. R. Bard, in Warwick, Rhode Island. Cited for the P4HB material and its expected absorption time.
  4. Fully resorbable poly-4-hydroxybutyrate (P4HB) mesh for soft tissue repair and reconstruction: A scoping reviewPubMed Central, National Library of Medicine2023. Cited for what P4HB is and its use in hernia and in plastic and reconstructive surgery. Several authors were affiliated with BD.

Vetted by

Stefan Rest, managing director of CBW Law

Stefan Rest

Managing Director, CBW Law

Stefan Rest has spent more than two decades advocating for consumers and helping people understand how the law may provide a path forward when they’ve been wronged. As Managing Director of CBW Law, he oversees client relations, the firm’s national law-firm network and new partnerships. He writes about developing litigation and consumer legal issues because the right information can help people recognize when their own story may matter.

Attorney advertising. The content of this website may be considered attorney advertising under the rules of certain jurisdictions. The information on this website is for general information purposes only and should not be taken as legal advice for any individual case or situation. Viewing this site does not create an attorney-client relationship. Prior results do not guarantee a similar outcome. Statutes, regulations and case law change, and the law differs from state to state.